Qiagen N.V. · NYSE:QGEN
Qiagen — Digene — Merger or Acquisition (June 2007)
50 slides from Qiagen's merger presentation, Jun 4, 2007
Slide 1: QIAGEN & Digene Announce Merger
QIAGEN – Digene: Creating a Leader in MDx, June 4, 2007 - 1 - Filed by: QIAGEN N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 under the Securities Exchange Act of 1934 Subject Company: Digene Corporation Exchange Act File No. 000-28194 Sample & Ass
Slide 2: Creating a Global Leader in Molecular Diagnostics
- 2 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics . . . Sample & Assay Technologies QIAGEN and Digene announced yesterday to combine the two companies to create the market and technology leading company in molecular diagnostics The Boards of Directors o
Slide 3: Combined Revenue Distribution – Highly Complementary
- 3 - QIAGEN/Digene – Creating a Leader in MDx Combined Revenue Distribution – Highly Complementary Based on Q1 2007 Europe 46% North America 39% Asia 13% North America 85% EU 12% North America 52% EU 36% Asia 9% Consumables 89% Consumables 92% Consumables 90% Instruments 10% Instruments 8% Instrume
Slide 4: QIAGEN and Digene at a Glance
- 4 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN and Digene at a Glance Sample & Assay Technologies 2003 2004 2005 2006 2007E Revenues Operating income Revenues excluding the synthetic DNA business unit, sold in Q2 2004 Market- and technology leader in Sample & Assay Technologies Founded: 1984
Slide 5: Highly Synergistic Capabilities and Assets
- 5 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Sample & Assay Technologies Highly Synergistic Capabilities and Assets Sales (Q1*4) Sales in MDx (approx) Sales strength Global North America Sales force size in MDx Sales force target in MDx Clinical La
Slide 6: Creating a Global Leader in Molecular Diagnostics
- 6 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Sample & Assay Technologies Who is QIAGEN? What is our strategy? What do we do in Diagnostics ?
Slide 7: QIAGEN Employees in Countries
- 7 - QIAGEN/Digene – Creating a Leader in MDx 2.000 QIAGEN Employees in 23 Countries Sample & Assay Technologies
Slide 8: Global Set-up With Three Headquarters In Major Markets
- 8 - QIAGEN/Digene – Creating a Leader in MDx Global Set-up With Three Headquarters In Major Markets Sample & Assay Technologies Maryland Shanghai/Shenzen Düsseldorf Switzerland = Automation Center of Excellence Hamburg = Assay Center of Excellence Valencia (1) = Customer satisfaction center Singap
Slide 9: USA: Country with Biggest Sales Organization
- 9 - QIAGEN/Digene – Creating a Leader in MDx USA: Country with Biggest Sales Organization Number of Employees in Sales: 770 Sample & Assay Technologies Direct Sales Australia Canada France Germany Italy Japan Switzerland UK USA Netherlands Belgium China Norway Austria Sweden Malaysia Denmark Finla
Slide 10: Slide 10
Slide 11: Slide 11
Slide 12: Slide 12
Slide 13: What is important to us? 3i's: Identity - Inspire - Impact
- 10 - QIAGEN/Digene – Creating a Leader in MDx What is important to us? 3i‘s: Identity - Inspire - Impact Sample & Assay Technologies I dentity Culture nspire Leadership I D E N T I T Y D E N Y I mpact Management T I T 1. Create and take ownership 2. Courage 3. Lead, motivate and empower 4. Be a ro
Slide 14: Slide 14
Slide 15: Slide 15
Slide 16: Slide 16
Slide 17: What Is Important To Us? Our Culture
- 11 - QIAGEN/Digene – Creating a Leader in MDx What Is Important To Us? Our Culture Sample & Assay Technologies 1. Act with Passion: We act with passion engagement and enthusiasm 2. Value Integrity: We are committed to integrity and respect for our customers, colleagues, partners and shareholders 3
Slide 18: Very High Commitment to our Employees
- 12 - QIAGEN/Digene – Creating a Leader in MDx Very High Committment to our Employees . . . . Sample & Assay Technologies Learning organization - “Investing in you” program Basic and advanced trainings Leadership programs Management campus and QIAGEN MBA International careers Working in global team
Slide 19: Slide 19
Slide 20: Providing Sample Preparation & Assay Technologies
- 14 - QIAGEN/Digene – Creating a Leader in MDx Providing Sample Preparation & Assay Technologies Sample & Assay Technologies
Slide 21: Slide 21
Slide 22: QIAGEN Technology and Innovation Technologies
- 16 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN Technology and Innovation Technologies Sample & Assay Technologies SAMPLE TECHNOLOGIES ASSAY TECHNOLOGIES Sample collection Sample stabilization Sample transport Sample disruption Targeted lysis Target capture Sample purification Inhibitor remov
Slide 23: Slide 23
Slide 24: Bringing Full Power To Our Customers
- 18 - QIAGEN/Digene – Creating a Leader in MDx Bringing Full Power To Our Customers Globally aligned Sales and Marketing Sample & Assay Technologies Customer focused – scaleable – critical mass One core = multiple channels We are Life Sciences Sales Pharma Key Account Manager Applied Testing Sales
Slide 25: MDx And Applied Testing Account For 35%
- 19 - QIAGEN/Digene – Creating a Leader in MDx MDx And Applied Testing Account For 35% Revenue breakdown for segments . . Sample & Assay Technologies Focus provides strength - new markets drive growth Focused core competency: Sample and assay technologies Four Markets: Life Sciences Academia Pharma
Slide 26: Slide 26
Slide 27: Slide 27
Slide 28: Slide 28
Slide 29: Creating a Global Leader in Molecular Diagnostics
- 20 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Sample & Assay Technologies Who is QIAGEN? What is our strategy? What do we do in Diagnostics ?
Slide 30: Molecular Diagnostics Growth Strategy
- 21 - QIAGEN/Digene – Creating a Leader in MDx Molecular Diagnostics Growth Strategy . . MDx Sample & Assay Technologies Multiple, Synergistic Channels – Focused Direct Sales Resources Direct sales OEM development OEM sales Direct Sales Growing direct sales force > 150 - (1) Focus on pathogens Mark
Slide 31: QIAGEN Has Developed More Than PCR Assays
- 22 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN Has Developed More Than 30 PCR Assays MDx Sample & Assay Technologies Cytomegalovirus Dengue virus Epstein-Barr virus Enterovirus Hepatitis A virus Hepatitis B virus Human immunodefienciy virus-1 Herpex simplex virus Influenzavirus Influenzaviru
Slide 32: Slide 32
Slide 33: Tangible Opportunities for Future Growth Synergies
- 24 - QIAGEN/Digene – Creating a Leader in MDx Tangible Opportunities for Future Growth Synergies Sample & Assay Technologies Significant Growth Synergies Exciting near-term product synergies: Multiplexing technologies for future genotyping application Sample preparation Next-generation assay techn
Slide 34: QIAGEN and Digene year partnership in Molecular Diagnostics
- 25 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN and Digene 15 year partnership in Molecular Diagnostics Sample & Assay Technologies >15 year partnership between QIAGEN and Digene Digene products leverage QIAGEN sample and assay technologies Example: RapidCapture system Core platform of Digene
Slide 35: QIAGEN and Digene - Direct Neighbors
- 26 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN and Digene - Direct Neighbors Germantown and Gaithersburg MD Sample & Assay Technologies Companies are 5 minutes apart (2.8 miles)
Slide 36: Slide 36
Slide 37: The Combination Accelerates QIAGEN's Molecular Strategy
- 28 - QIAGEN/Digene – Creating a Leader in MDx The Combination Accelerates QIAGEN’s Molecular Strategy Sample & Assay Technologies Digene’s highly focused strategy in MDx is a unique fit with QIAGEN QIAGEN’s strategy: leadership in “Sample & Assay Technologies” – in research, pharma, applied testin
Slide 38: The Combination Accelerates Digene's Development Goals
- 29 - QIAGEN/Digene – Creating a Leader in MDx The Combination Accelerates Digene’s Development Goals Sample & Assay Technologies QIAGEN’s unparalleled sample and assay technology breadth creates opportunities for future: Adds key assay technologies such as multiplexing (QIAplex), PCR, isothermal t
Slide 39: World-Class Capabilities & Organization Ensure Success
- 30 - QIAGEN/Digene – Creating a Leader in MDx World-Class Capabilities & Organization Ensure Success Sample & Assay Technologies Great breadth and depth of management team Strong leaders from both companies Leading expertise in molecular diagnostics and life sciences Strong foundation for collabor
Slide 40: Slide 40
Slide 41: Slide 41
Slide 42: Slide 42
Slide 43: Four Phases to an effective Integration of Digene
- 31 - For Internal Use Only Four Phases to an effective Integration of Digene Sample & Assay Technologies Phase 0 Pre-Process planning Phase 2 Detailed planning & decision making Phase 3 Implementation & execution Phase 1 Issue identification and action planning Appoint and launch integration teams
Slide 44: Integration should be accomplished in months
- 32 - QIAGEN/Digene – Creating a Leader in MDx Integration should be accomplished in 6 – 12 months Sample & Assay Technologies Load dependent on requirements Handover Resources FTE Integration Accomplished Line function Take over responsibilities Jul Jun May Mar Apr Jan Feb May Jun Jul Oct Nov Aug
Slide 45: Project Structure for Integration
- 33 - QIAGEN/Digene – Creating a Leader in MDx Project Structure for Integration Sample & Assay Technologies Special Projects Functional Projects Business Projects Responsible for the bulk of the integration Made up from representatives of the different functions of both companies Develop guide-lin
Slide 46: Doug Liu – VP Global Operations – QIAGEN
- 34 - QIAGEN/Digene – Creating a Leader in MDx Doug Liu – VP Global Operations – QIAGEN . Sample & Assay Technologies Douglas Liu VP Global Operations Doug Liu joined QIAGEN in 2005 MBA from Boston University Science degree from the University of Illinois Multifunctional background in diagnostic In
Slide 47: Doug White – SVP Sales & Marketing – Digene
- 35 - QIAGEN/Digene – Creating a Leader in MDx Doug White – SVP Sales & Marketing – Digene . . . Sample & Assay Technologies Douglas White SVP Sales & Marketing Americas and Asia Pacific Doug White joined Digene in 2003 Started as VP Sales & Marketing North America Oversees commercial operations in
Slide 48: Joe Slattery – Chief Financial Officer Digene
- 36 - QIAGEN/Digene – Creating a Leader in MDx . . . Joe Slattery – Chief Financial Officer Digene Sample & Assay Technologies Joseph P. Slattery Chief Financial Officer and Senior Vice President Joe Slattery joined Digene in 1996 Corporation’s finance, accounting, investor relations, treasury, inf
Slide 49: Thomas Schweins – VP Marketing & Strategy QIAGEN
- 37 - QIAGEN/Digene – Creating a Leader in MDx Thomas Schweins – VP Marketing & Strategy QIAGEN . . . Sample & Assay Technologies Thomas Schweins VP Marketing & Strategy Thomas Schweins joined QIAGEN in 2004 Biochemistry, University Hannover Business Adminstration, USC Los Angeles PhD, Max Planck I
Slide 50: Questions and Answers
QIAGEN – Digene: Creating a Leader in MDx, June 4, 2007 - 38 - Sample & Assay Technologies Questions and Answers If you have further questions: Call +240-686 7362 E-mail [email protected] Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-loo